
The first human trials of an Ebola vaccine will begin in the United States next week, officials said Thursday, after the World Health Organization (WHO) warned that more than 20,000 people could end up being infected before the outbreak in West Africa can be stopped, dpa reported.
The American National Institutes of Health (NIH) said it will sponsor the first trial of the vaccine, which it co-developed with drug manufacturer GlaxoSmithKline, at its clinical centre in Bethesda, Maryland. Other test sites will include Britain and potentially Gambia, Mali and Nigeria.
The trial is being fast-tracked as the Ebola outbreak continues to gather pace in West Africa, with the death toll in the region now at 1,552, according to the WHO.
The Geneva-based organization said 3,069 suspected or confirmed cases had been reported in Guinea, Liberia, Nigeria and Sierra Leone.
However, the WHO estimates the actual number of cases may be two to four times higher than currently reported.
More than 40 per cent of all cases occurred within the past three weeks, pointing to an acceleration of the infection rates in the region, WHO said.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor